---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-076458"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T18:45:16.762369+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Candel's CAN-2409 Phase 3 meets primary endpoint (p=0.0155) in localized prostate cancer; ASCO presentation June 3

## Summary
- Statistically significant improvement in DFS (p=0.0155) with 30% risk reduction (HR 0.7) for CAN-2409 plus radiotherapy vs placebo plus radiotherapy.
- Secondary endpoints met: 80.4% pathological complete response at two-year biopsy vs 63.6% control (p=0.0015); higher PSA nadir <0.2 ng/ml (67.1% vs 58.6%, p=0.0164).
- CAN-2409 well tolerated; treatment-related serious adverse events low (1.7% drug arm vs 2.2% control).
- Company plans to submit Biologics License Application for CAN-2409 in Q4 2026.
- Data to be presented at ASCO 2025 oral abstract session on June 3, 2025.

## SEC filing metadata
- accession: 0000950170-25-076458
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017025076458/0000950170-25-076458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017025076458/cadl-20250522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-076458
- JSON: https://secwatch.observer/filing/0000950170-25-076458.json
- Plain text: https://secwatch.observer/filing/0000950170-25-076458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.